Wellington Management Group
NRIX icon

Wellington Management Group’s Nurix Therapeutics NRIX Stock Holding History

Wellington Management Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.11M Buy
334,138
+12,778
+4% +$218K ﹤0.01% 1344
2026
Q1 		$4.98M Buy
321,360
+46,182
+17% +$766K ﹤0.01% 1405
2025
Q4 		$5.22M Buy
275,178
+19,388
+8% +$279K ﹤0.01% 1404
2025
Q3 		$2.36M Sell
255,790
-1,209,263
-83% -$12.6M ﹤0.01% 1591
2025
Q2 		$16.7M Sell
1,465,053
-1,723,689
-54% -$18.6M ﹤0.01% 1032
2025
Q1 		$37.9M Sell
3,188,742
-397,863
-11% -$6.65M 0.01% 770
2024
Q4 		$67.6M Buy
3,586,605
+104,500
+3% +$2.4M 0.01% 635
2024
Q3 		$78.2M Buy
3,482,105
+280,240
+9% +$6.35M 0.01% 593
2024
Q2 		$66.8M Buy
3,201,865
+2,968,729
+1,273% +$46.2M 0.01% 635
2024
Q1 		$3.43M Buy
233,136
+27,812
+14% +$299K ﹤0.01% 1419
2023
Q4 		$2.12M Buy
205,324
+60,271
+42% +$413K ﹤0.01% 1483
2023
Q3 		$1.14M Buy
145,053
+4,163
+3% +$38K ﹤0.01% 1586
2023
Q2 		$1.41M Buy
140,890
+70,361
+100% +$718K ﹤0.01% 1548
2023
Q1 		$626K Sell
70,529
-2,475
-3% -$25.8K ﹤0.01% 1792
2022
Q4 		$802K Sell
73,004
-1,525
-2% -$18.4K ﹤0.01% 1688
2022
Q3 		$971K Buy
74,529
+21,425
+40% +$339K ﹤0.01% 1661
2022
Q2 		$673K Sell
53,104
-789,269
-94% -$8.95M ﹤0.01% 1750
2022
Q1 		$11.8M Sell
842,373
-319,943
-28% -$5.68M ﹤0.01% 1161
2021
Q4 		$33.6M Sell
1,162,316
-63,742
-5% -$1.93M 0.01% 955
2021
Q3 		$36.7M Sell
1,226,058
-168,833
-12% -$5.21M 0.01% 914
2021
Q2 		$37M Buy
1,394,891
+34,465
+3% +$1.01M 0.01% 925
2021
Q1 		$42.3M Sell
1,360,426
-1,087,158
-44% -$41.1M 0.01% 848
2020
Q4 		$80.3M Sell
2,447,584
-920,938
-27% -$30.5M 0.01% 647
2020
Q3 		$117M Buy
+3,368,522
New +$84.9M 0.02% 489

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group's NRIX Position: Q2 2026 in Review

Wellington Management Group increased its Nurix Therapeutics (NRIX) stake by 4% in Q2 2026, buying an estimated $218K and bringing the position to 334,138 shares worth $8.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1344.

Wellington Management Group first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $117M in Q3 2020. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Wellington Management Group held 334,138 shares of Nurix Therapeutics worth $8.11M as of Q2 2026.
  • Wellington Management Group bought 12,778 Nurix Therapeutics shares in Q2 2026, an estimated $218K.
  • Nurix Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1344 holding.
  • Wellington Management Group first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Wellington Management Group's Nurix Therapeutics position peaked at $117M in Q3 2020.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.